Home » Topics » BioWorld Science

BioWorld Science
RSS

U.S. investigators identify new apoptosis inducers for cancer

Oct. 1, 2019

AnaptysBio reports phase II interim data on ANB-019 in generalized pustular psoriasis

Oct. 1, 2019

FDA issues complete response letter for PT-010 for COPD

Oct. 1, 2019

Janssen presents free fatty acid FFA1 and/or FFA4 receptor agonists

Oct. 1, 2019

Chinese investigators patent CDK4 and/or CDK6 inhibitors

Oct. 1, 2019

Phase III RESTORE-IMI 2 trial of Recarbrio in HABP/VABP meets primary endpoint

Oct. 1, 2019

Annexon reports phase Ib data on ANX-005 in Guillain-Barre syndrome

Oct. 1, 2019

FDA approves Invokana for use in patients with type 2 diabetes and diabetic kidney disease

Oct. 1, 2019

Phase II results for TAS-115 for the treatment of IPF presented

Oct. 1, 2019

Brain tumors, metastases form synapses with neurons

Oct. 1, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...